David Abrams Akebia Therapeutics, Inc. Transaction History

Abrams Capital Management, L.P.

  • $3.12 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021
SELL
$2.22 - $3.78 $12.6 Million - $21.4 Million
-5,656,462 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$5.39 - $9.15 $24.5 Million - $41.5 Million
4,537,176 Added 405.36%
5,656,462 $31.3 Million
Q3 2018

Nov 09, 2018
BUY
$7.44 - $10.65 $8.33 Million - $11.9 Million
1,119,286 New
1,119,286 $9.88 Million

Others Institutions Holding AKBA

# of Institutions
120
Shares Held
54.8M
Call Options Held
291K
Put Options Held
179K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $342M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track David Abrams's Portfolio

Track David Abrams Portfolio

Follow David Abrams (Abrams Capital Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrams Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Abrams Capital Management, L.P. and David Abrams with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email